F Dx Advisors, Inc. Intellia Therapeutics, Inc. Transaction History

F Dx Advisors, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$23.16 - $32.34 $5,905 - $8,246	-255 Reduced 2.41%	10,321 $315,000
Q3 2023 Nov 02, 2023	SELL	$31.62 - $45.78 $190,858 - $276,328	-6,036 Reduced 36.34%	10,576 $334,000
Q2 2023 Jul 17, 2023	BUY	$34.58 - $46.03 $95,509 - $127,134	2,762 Added 19.94%	16,612 $677,000
Q4 2022 Feb 09, 2023	BUY	$33.21 - $62.69 $5,180 - $9,779	156 Added 1.14%	13,850 $483,000
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $62,762 - $83,458	1,164 Added 9.29%	13,694 $766,000
Q2 2022 Aug 03, 2022	BUY	$38.49 - $76.21 $93,107 - $184,351	2,419 Added 23.92%	12,530 $649,000
Q1 2022 May 03, 2022	SELL	$58.27 - $118.99 $757 - $1,546	-13 Reduced 0.13%	10,111 $735,000
Q4 2021 Feb 01, 2022	BUY	$100.76 - $138.36 $2,619 - $3,597	26 Added 0.26%	10,124 $1.2 Million
Q3 2021 Oct 08, 2021	SELL	$132.37 - $176.78 $260,636 - $348,079	-1,969 Reduced 16.32%	10,098 $1.36 Million
Q2 2021 Aug 05, 2021	SELL	$60.88 - $161.91 $444,180 - $1.18 Million	-7,296 Reduced 37.68%	12,067 $1.95 Million
Q1 2021 Apr 14, 2021	BUY	$46.59 - $83.68 $829,721 - $1.49 Million	17,809 Added 1146.01%	19,363 $1.55 Million
Q1 2021 Apr 13, 2021	SELL	$46.59 - $83.68 $971,634 - $1.75 Million	-20,855 Reduced 93.07%	1,554 $124,000
Q4 2020 Feb 08, 2021	BUY	$18.83 - $63.53 $9,659 - $32,590	513 Added 2.34%	22,409 $1.22 Million
Q3 2020 Nov 12, 2020	BUY	$17.47 - $24.93 $171,625 - $244,912	9,824 Added 81.38%	21,896 $435,000
Q2 2020 Jul 22, 2020	BUY	$11.14 - $22.87 $134,482 - $276,086	12,072 New	12,072 $254,000

316

91.7M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $722M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.